Sanofi jumps into a pivotal study for next-gen Pompe drug
Sanofi has added another badly-needed drug to its late-stage portfolio. The drug, dubbed neoGAA, is being advanced by its big Genzyme unit in Boston, which has just started a Phase III trial for a next-gen enzyme replacement therapy for Pompe disease.
Sanofi reports that the first of 96 patients have been treated with their therapy, which they describe as a second-generation approach to enzyme replacement, a field Genzyme helped pioneer.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
